HPV Vaccine Age Range and Gender Inclusion

Expanding HPV vaccination beyond the current adolescent age range now includes adults up to age 45 in some countries, a shift that reduces cervical cancer risk by up to 90% in vaccinated populations. Compared to the volatile annual effectiveness of the #8 flu vaccine, whose protection can drop to 10%, the HPV vaccine maintains near-consistent efficacy of over 85% across recommended ages. Debate persists on gender inclusion; while 45 countries now offer the vaccine to boys, others limit it solely to girls, leaving an estimated 300 million males unprotected globally. This initiative outperforms #5 Vaccine Equity and Global Access in precision, targeting a single virus while bridging access gaps for underserved groups, including transgender populations who face higher HPV-related cancer rates.